We first analysed the transcriptomes of SMARCB1-deficient tumors with ascertained diagnoses of RT (n = 16), and SMARCB1-deficient non rhabdoid tumors (SD-NRT, n = 16) with ascertained diagnosis of epithelioid sarcomas (ES, n = 8), renal medullary carcinoma (RMC, n = 5) and undifferentiated chordomas (UC, n = 3); these tumors constituted the “training set” (see material and methods, clinical and genetic features in Table 1). This evidence concerns the gene SMARCB1 and kidney medullary carcinoma.